Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.

Patients with primary resistance to crizotinib displayed unfavorable survival outcomes and the underlying mechanism cannot be identified in clinical features. Nevertheless, next-generation ALK inhibitors and chemotherapy after crizotinib progression could confer a therapeutic and survival benefit in this population.